Cryo-Cell International Inc. - CCEL STOCK NEWS

Cryo-Cell International, Inc. (CCEL) has announced its common stock is listed on the Nasdaq Capital Market as of August 31, 2021. This milestone marks an achievement in meeting Nasdaq's stringent requirements and aims to enhance liquidity and broaden the shareholder base. Chairman David Portnoy expressed optimism that this uplisting will reduce the valuation gap between market and intrinsic value. Cryo-Cell is transitioning into a biopharmaceutical company, providing experimental treatments at the upcoming Cryo-Cell Institute for Cellular Therapies.

Cryo-Cell International (CCEL) has acquired an 8,326 sq. ft. facility in Durham, NC, for its Institute for Cellular Therapies, strategically located near the Raleigh-Durham International Airport. The clinic aims to provide FDA-approved clinical trials for patients in need of cord blood therapies by early 2022. This facility will employ advanced technology and child-friendly layout while adhering to COVID safety guidelines. The treatments target various conditions, including autism spectrum disorders and cerebral palsy.

Cryo-Cell International, the world’s first cord blood bank, announced that Chairman and Co-CEO, David Portnoy, will present at the Q3 Virtual Investor Summit on August 18, 2021, at 2:45 PM EDT. The 30-minute session will include a 20-minute corporate overview followed by a 10-minute Q&A. In February 2021, Cryo-Cell transformed into a vertically integrated cellular therapy company through a license agreement with Duke University, set to treat patients at its first infusion clinic opening in early 2022. The event can be accessed via registration.

Cryo-Cell International, Inc. (CCEL) reported its fiscal Q2 2021 results with a revenue decrease of 8% to $7.21 million, down from $7.87 million in Q2 2020. The company generated $7.16 million in processing and storage fees. Net income rose to $1.17 million, or $0.15 per basic share, from $953,000, or $0.13 per basic share in the prior year. Cost reductions in sales and administrative expenses contributed to net income growth despite lower revenues. Cryo-Cell continues to expand its operations and maintain quality standards with FDA registration and AABB accreditation.

Cryo-Cell International is conducting two pivotal clinical studies: MASC for COVID-19 related Acute Respiratory Distress Syndrome and MISTIC for children with Multisystem Inflammatory Syndrome associated with COVID-19. MASC has completed Phase 1 and is enrolling for Phase 2, while MISTIC is in Phase 1 enrollment. Both studies utilize human cord tissue derived mesenchymal stromal cells. The ongoing research underscores Cryo-Cell's commitment to advancing regenerative medicine and improving patient outcomes amid the ongoing pandemic.

Cryo-Cell International, Inc. (OTC: CCEL) reported its fiscal first quarter results for 2021, citing revenues of $6.86 million, a decrease from $7.62 million in Q1 2020. The revenue comprised $6.74 million from processing and storage fees, $38,000 from product sales, and $84,000 from public banking. Net income was approximately $694,000, consistent with the prior year. The company is optimistic about future opportunities tied to its licensing agreement with Duke University, despite challenges posed by the COVID-19 pandemic affecting birth rates.

Cryo-Cell International, Inc. (CCEL) has entered a collaborative licensing agreement with Duke University to utilize proprietary processes and regulatory data pertaining to cord blood and tissue. This agreement allows Cryo-Cell to explore potential treatments for conditions with limited FDA approved therapies, including cerebral palsy, autism, multiple sclerosis, and COVID-19. Cryo-Cell is focusing on expanding its core business units, including biopharmaceutical manufacturing, pending necessary FDA approvals. The partnership raises the possibility of uplisting the stock to NASDAQ.

Cryo-Cell International, a leader in private cord blood banking, reported its fiscal 2020 results with revenues of $31.1 million, a slight decline from $31.8 million in fiscal 2019. The company noted net income of $3.6 million, or $0.48 per basic share, an improvement from $2.3 million in 2019. Key revenue components included $29.5 million from processing and storage fees. Despite decreasing costs, the company faced a $1.1 million loss due to the cancellation of a revenue-sharing agreement. Impairment charges on inventory were also noted, amounting to $1.3 million for 2020.

Cryo-Cell International, Inc. (OTC: CCEL) reported its third-quarter financial results for fiscal 2020, revealing consolidated revenues of $8.1 million, slightly down from $8.2 million in Q3 2019. Net income was reported at $784,000, or $0.10 per share, a decline from $1,116,000, or $0.14 per share, in the prior year. Notably, the company incurred a one-time expense of $1,070,900 due to the termination of the Erie Group Revenue Sharing Agreement. Despite challenges, management expressed optimism regarding a licensing agreement with Duke University.